Thyroid Eye Disease
64
8
17
25
Key Insights
Highlights
Success Rate
76% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
12.5%
8 terminated out of 64 trials
75.8%
-10.7% vs benchmark
41%
26 trials in Phase 3/4
28%
7 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (64)
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease